Sensus Healthcare has announced a U.S. distribution agreement with Mattioli Eng. Italia S.P.A. for its TransDermal Infusion System.
The TransDermal Infusion System, a noninvasive drug delivery system, was cleared by the U.S. Food and Drug Administration (FDA) for the local administration of ionic drug solutions into the body for medical purposes, and can be used as an alternative to injections.
The system will be marketed to dermatologists for skin rejuvenation treatments, pre-laser treatments, pre- and post-plastic surgery and other applications. Sensus will also make rental programs and leasing facilities available.
The system allows allows for the noninvasive delivery of drugs that are otherwise not able to be absorbed including Botox, hyaluronic acid, lidocaine, collagen and others typically used in aesthetic procedures.
“We are delighted to collaborate with such a globally recognized and highly respected firm as Mattioli Eng. Italia,” said Joe Sardano, chairman and CEO of Sensus Healthcare. “The device, which we intend to trademark as ‘TransDermal Infusion’ under the Sensus brand, is FDA-cleared for use on any part of the body currently treated with needle injections. This permits various fillers and other injectables to be administered without pain and without patient downtime. We believe this needle-free treatment will be embraced by aesthetic dermatology clinics as a competitive advantage and an advance in patient care.”
Sensus plans to begin marketing this System to dermatologists nationwide beginning immediately.
